APA (7th ed.) Citation

Ray-Coquard, I., Kaminsky-Forrett, M., Joly, F., Montané, L., Bello Roufai, D., Savoye, A., . . . Lecuru, F. (2021). 819TiP COLIBRI trial (GINECO-CE108b): A multicenter, window study evaluating immune impact and safety of nivolumab in combination with ipilimumab before initial radio-chemotherapy (RTCT) treatment for locally advanced cervix cancer. Annals of Oncology, 32, S770. https://doi.org/10.1016/j.annonc.2021.08.1261

Chicago Style (17th ed.) Citation

Ray-Coquard, I.L, et al. "819TiP COLIBRI Trial (GINECO-CE108b): A Multicenter, Window Study Evaluating Immune Impact and Safety of Nivolumab in Combination with Ipilimumab Before Initial Radio-chemotherapy (RTCT) Treatment for Locally Advanced Cervix Cancer." Annals of Oncology 32 (2021): S770. https://doi.org/10.1016/j.annonc.2021.08.1261.

MLA (9th ed.) Citation

Ray-Coquard, I.L, et al. "819TiP COLIBRI Trial (GINECO-CE108b): A Multicenter, Window Study Evaluating Immune Impact and Safety of Nivolumab in Combination with Ipilimumab Before Initial Radio-chemotherapy (RTCT) Treatment for Locally Advanced Cervix Cancer." Annals of Oncology, vol. 32, 2021, p. S770, https://doi.org/10.1016/j.annonc.2021.08.1261.